Fibrosis Pulmonar
Longitudinal changes in KL6 levels predict acute exacerbation in fibrotic interstitial lung disease
Pirfenidone and risk of lung cancer development in idiopathic pulmonary fibrosis: a nationwide population-based study
Quality of life in idiopathic pulmonary fibrosis in Latin American countries
High antinuclear antibody titer is associated with increased mortality risk in patients with idiopathic pulmonary fibrosis
Real-world therapeutic performance of pirfenidone for connective tissue disease-associated interstitial lung diseases
Clinical and economic burden of acute exacerbations of idiopathic pulmonary fibrosis: a prospective observational study in Spain (OASIS study)
Long-term radiological and pulmonary function abnormalities at 3 years after COVID-19 hospitalisation: a longitudinal cohort study
Antifibrotic treatment adherence, efficacy and outcomes for patients with idiopathic pulmonary fibrosis in Spain: a real-world evidence study
Pirfenidona LP en secuelas Post-COVID
Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience
Prognostic significance of antifibrotic agents in idiopathic pulmonary fibrosis after initiation of long-term oxygen therapy
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy.
Secuelas pulmonares de COVID-19: Enfoque en la enfermedad pulmonar intersticial
Factors associated with dose reduction of pirfenidone in patients with idiopathic pulmonary fibrosis: A study based on realworld clinical data.
